Most Clicked StoriesMore >


Patient advocates caught in the middle of drug-price debate

PCMA SmartBrief | Sep 28, 2016

Most patient advocacy groups have stayed quiet amid the controversy over drug prices, and some of those that have weighed in on the issue have taken the pharmaceutical industry's stance of placing blame on payers. Many advocacy groups receive funding from drugmakers and work closely with them on drug development and approval. The New York Times (free-article access for SmartBrief readers) (09/27)


UnitedHealth drops Lantus, Neupogen from formulary

PCMA SmartBrief | Sep 22, 2016

PBMs negotiated big discounts on expensive HCV drugs

PCMA SmartBrief | Sep 22, 2016

PCMA suggests ways to reduce opioid abuse, lower drug prices

PCMA SmartBrief | Sep 26, 2016

PCMA testifies before House subcommittee, offers policy options to curb Rx abuse, reduce costs

PCMA SmartBrief | Sep 23, 2016

Novum follows in footsteps of Valeant, Turing, Mylan

PCMA SmartBrief | Sep 27, 2016

PCMA: MAC lists help payers keep drug prices under control

PCMA SmartBrief | Sep 26, 2016

Release of draft guidance for biosimilar interchangeability moved by FDA

PCMA SmartBrief | Sep 23, 2016

Abbott reps pulled out all the stops to promote OxyContin

PCMA SmartBrief | Sep 22, 2016

Mylan CEO grilled in hearing over EpiPen price hikes

PCMA SmartBrief | Sep 22, 2016


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more